CAS: 6553-96-4; 2,4,6-Triisopropylbenzene-1-Sulfonyl Chloride

该化合物是一种有机化合物,其特点是附于苯环的全氟辛烷磺酸功能组,该元素组还被三个异丙基组所取代,这种结构具有严重的阻塞性,影响其再活性和溶性;众所周知,该元素组具有高度反应性,特别是在核生殖性替代反应方面,使该化合物在有机合成中有用,特别是用于将全氟辛烷磺酸组引入各种子体.该化合物一般没有色,没有黄色液体或固态,取决于其纯度和形态.该化合物对湿度敏感,因为它可以水分形成相应的磺酸.在处理该物质时,安全防范是必要的,因为它可能对皮肤和粘膜具有腐蚀性和刺激性.适当储存在冷干燥的地方,远离湿度和不相容的物质,对于保持其稳定性和再活性至关重要.

结构式图片

欧盟法规

REACH注册ECHA物质C&L通报REACH预注册

上下游产品

CAS号717-74-8 1,3,5-三异丙苯 | CAS号39085-59-1 2,4,6-三异丙基苯磺酰基肼 | CAS号54230-60-3 1-(2,4,6-三异丙基苯磺... | CAS号36982-84-0 2,4,6-三异丙基苯磺酰叠氮化物 | CAS号50257-40-4 1-(2,4,6-三异丙基苯基磺酰)咪唑 | CAS号717-74-8 1,3,5-三异丙苯 | CAS号22693-41-0 2,4,6-三异丙基苯硫酚 | CAS号63734-76-9 4-硝基-1-[[2,4,6-... | CAS号105536-22-9 2,4,6-三异丙基苯磺胺 | CAS号114021-22-6 3',5'-bis-o-(t-... | CAS号20875-34-7 1,3,5-tri(propa...

合成工艺路线路线简述

    三異丙苯置于氯磺酸,Sodium Chloride体系中,用65%的收率获得产物2,4,6-三异丙基苯磺酰氯
    参考文献:芳烃磺酰氯的丙烷分解:磺酰硫处的亲核取代
    标题:芳烃磺酰氯的丙烷分解:磺酰硫处的亲核取代
    摘要:我们研究了在303-323 K时丙-1-醇和丙-2-醇对芳烃磺酰氯的溶剂分解机理.动力学曲线适合一阶动力学.反应性随供电子取代基的增加而增加.芳烃磺酰氯的邻烷基取代衍生物显示出增加的反应性,但这种"正向"邻效应的起源仍不清楚.可能,邻位甲基限制了绕c键的旋转,从而促进了亲核试剂的攻击.就亲核性空间效应而言,未发现丙-1-醇和丙-2-醇的相关反应性变化.所有底物的等动力学关系的存在表明该系列的单一机制.两种醇中所有底物的溶剂分解反应均显示等速温度(t Iso)接近工作温度范围,这表明该过程受到次级反应性因素的影响,该因素可能是ts中的空间性质.溶剂化在该反应中起重要作用,调节反应性.在一些情况下,存在吨-Bu代替我在对位位置导致第一溶剂化壳的变化,从而增加了反应能量(约1 Kj.mol-1).所得结果表明,芳烃磺酰氯对丙-1-醇和丙-2-醇的溶剂化动力学机制与在meoh和etoh中相同,其中双分子亲核取代(s
    DOI:10.1002/poc.3753

    海关参考信息

    专利信息


    专利号:US-2022401910-A1
    优先权日:2019-12-02
    标 题 :Apparatus for the synthesis of oligonucleotides and process for the preparation thereof
    发明人:AEMISSEGGER ANDREAS; DUGOVIC BRANISLAV; JAUKER MARIO; STAUSS MARTIN
    权利人:BACHEM AG
    摘要:The present invention provides apparatuses and methods for the synthesis of oligonucleotides and related compounds. In particular, the present invention allows to effectively prepare reagents to be fed into an apparatus for the synthesis of such oligomers.

    专利号:US-7705136-B2
    优先权日:2005-02-25
    标 题 :Synthesis of 3′-, or 5′-, or internal methacrylamido-modified oligonucleotides
    发明人:GOLOVA JULIA B; CHERNOV BORIS K
    权利人:UCHICAGO ARGONNE LLC
    摘要:New modifiers were synthesized for incorporation of a methacrylic function in 3′-, 5′- and internal positions of oligonucleotides during solid phase synthesis. A modifier was used for synthesis of 5′-methacrylated oligonucleotides for preparation of microarrays by a co-polymerization method.

    专利号:US-2004054161-A1
    优先权日:2002-09-13
    标题 :Stepwise solid-phase synthesis of peptide-oligonucleotide conjugates and supports therefor
    发明人:ANTOPOLSKII MAXIM; AZHAYEVA ELENA; AZHAYEV ALEX
    权利人:GLEN RES CORP
    摘要:A support for peptide-oligonucleotide conjugate synthesis includes an article of manufacture according to the formula: n n n wherein: (a) substitutent A includes a polymeric base material and/or a silica base material; (b) one of substituents B and C includes an NHFmoc-containing group and/or a peptide-containing group; (c) one of substituents B and C includes an NHBoc-containing group, an O-DMTr-containing group, and/or an oligonucleotide-containing group; and (d) each X independently represents â•?O, S, and/or NH. Suitable supports include those according to the formula: n n n wherein substituents A, B, and C have the meanings described above. When used to synthesize a peptide-oligonucleotide conjugate, the resulting conjugate may have the formula: n n n wherein substituent B includes a peptide and substituent C includes an oligonucleotide.

    专利号:WO-2022229980-A1
    优先权日:2021-04-28
    标 题 :A process for preparation of anti viral drug molnupiravir (eidd 2801) from d-ribose
    发明人:JOHN JUBI; KOKKUVAYIL VASU RADHAKRISHNAN; LANKALAPALLI RAVI SHANKAR; DODDAMANI SHRIDEVI; PUTHIYAPARAMBATHU SHARATHNA; PANIKKASSERY RAVI NITHA; AYYAPPANPILLAI AJAYAGHOSH
    权利人:COUNCIL SCIENT IND RES
    摘要:Present invention relates to a short and cost-effective synthetic process for synthesis of a broad-spectrum antiviral drug Molnupiravir (EIDD 2801) of formula I. Particularly, the present invention relates to a process for synthesis of a broad-spectrum antiviral drug EIDD 2801 via a short synthetic route from the basic starting material D-ribose. The present invention also decreases the usage of purification processes such as column chromatography after individual steps in comparison to the prior arts which makes the present process a green alternative. Finally, the use of cheap raw materials makes the process cost effective and industrially viable.

    专利号:WO-2025082632-A1
    优先权日:2023-10-16
    标 题:Method and composition for oligonucleotide synthesis
    发明人:SAITO MASAHARU
    权利人:BACHEM HOLDING AG
    摘要:The invention pertains to a method for the synthesis of oligonucleotides using pseudo solid-phase protecting groups, wherein said method comprises a step of subjecting a solution comprising a component (C-0)# to one or more aqueous extractions, wherein the organic phase comprises the component (C-0)#. Said component (C-0)# is a nucleoside or an oligonucleotide, which is covalently bonded to a pseudo solid-phase protecting group and comprises a free backbone hydroxyl group. The aqueous phase of each of said one or more aqueous extractions has a pH-value in the range of 4-7.

    专利号:US-2008221303-A1
    优先权日:2004-02-18
    标 题:Method for the Preparation of Peptide-Oligonucleotide Conjugates
    发明人:KATZHENDLER JEHOSHUA; KLAUZNER YAKIR; BEYLIS IRENA; MIZHIRITSKII MICHAEL; SHPERNAT YAACOV; ASHKENAZI BORIS; FRIDLAND DMITRI
    权利人:KATZHENDLER JEHOSHUA; KLAUZNER YAKIR; BEYLIS IRENA; MIZHIRITSKII MICHAEL; SHPERNAT YAACOV; ASHKENAZI BORIS; FRIDLAND DMITRI
    摘要:The present invention relates to the synthesis of peptide-oligonucleotide conjugates (POC). More specifically, the invention relates to a novel method for the preparation of peptide-oligonucleotide conjugates, which can be conducted under mild conditions on solid support, can be performed manually or by a synthesizer, can be used to synthesize alternating sequences of peptides and oligonucleotides, and is applicable to the synthesis of a wide variety of peptide-oligonucleotide conjugates constructed from alternate peptide and oligonucleotide blocks.
    苏州润森药物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.rosen-chemicals.com
    企业联系电话:17712495068👤
    📞苏州润森药物科技有限公司 ⚠️参考联系方式
    联系人:杨总
    电话:17712495068
    手机:18751140360
    传真:QQ:640192082
    邮箱:sales@rosen-chemicals.com
    通信地址: 江苏省苏州高新区新亭路5号1幢2楼
    邮编: 235300
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:江苏省苏州高新区新亭路5号1幢2楼
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    上海共价化学科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.medpep.com/
    电话: 021-65566949 13901795941👤
    📞上海共价化学科技有限公司 ⚠️参考联系方式

    销售电话:021-65566949 13901795941
    邮箱:market@medpep.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Croft, R. A.; Bull, J. A., Science of Synthesis Knowledge Updates, (2018) 4, 383.
    摘要:Kashemirov, B. A.; Błażewska, K.; Justyna, K.; Lyu, J.; McKenna, C. E., Science of Synthesis Knowledge Updates, (2021) 1, 483.
    摘要:Schafer, E. W., Jr., and W. A. Bowles Jr. 1985. Acute oral toxicity and repellency of 933 chemicals to house and deer mice. Archives of Environmental Contamination and Toxicology 14:111-129.
    摘要:Cellnik, T.; Jo, W.; Healy, A., Science of Synthesis: Knowledge Updates, (2024) 2, 366.
    参考文献:10.1023/b:rubi.0000023106.52513.6a
    摘要:Ignatov DV, Prokof'ev IuI, Timofeev VP, Misharin AIu. [Palmitates of isomeric 15-oxygenated delta8(14)-sterols]. Bioorg Khim. 2004 Mar;30(2):208–14. doi: 10.1023/b:rubi.0000023106.52513.6a.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知